The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) is a national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics. Data (genomics, proteomics, imaging), assays, and reagents are made available to the public as a Community Resource to accelerate cancer research and advance patient care. CPTAC has been conducted in multiple phases. For the phase 3 prospective data collection activities TCIA has partnered with CPTAC to host both the radiology and pathology imaging data generated by the project. The other data types will be hosted in separate databases managed by the CPTAC program. TCIA will provide links to these resources as they become publicly available.
CPTAC Imaging Special Interest Group
You can join the CPTAC Imaging Special Interest Group to be notified of webinars & data releases, collaborate on common data wrangling tasks and seek out partners to explore research hypotheses!
CPTAC Phase 3 Histopathology and Radiology Imaging
CPTAC imaging data is being made available on a quarterly release schedule. Learn more about each cancer type by clicking on the collection names in the table below. Data currently available is listed below. Clicking on the number of subjects will take you to these data portals with that particular cancer type pre-selected. You can access the radiology and pathology data directly from the respective data portals.
Collection | Cancer Type | Location | Radiology Modalities | Radiology (Subjects)* | Pathology (Subjects)** |
| CPTAC-AML | Acute Myeloid Leukemia | Bone Marrow | -- | -- | 56 |
|---|---|---|---|---|---|
Clear Cell Carcinoma | Kidney | CR, CT, DX, MR, SR | 222 | ||
Cutaneous Melanoma | Skin | CR, CT, MR | 92 | ||
Glioblastoma Multiforme | Brain | CR, CT, DX, MR, NM, SC | 189 | ||
| CPTAC-HNSCC | Head and Neck Squamous Cell Carcinoma | Head-Neck | CT, SC, MR | 55 | 112 |
Squamous Cell Carcinoma | Lung | CR, CT, DX, NM, PT | 212 | ||
Adenocarcinoma | Lung | CT, MR, PT, CR, DX, NM | 244 | ||
Ductal Adenocarcinoma | Pancreas | CT, MR, DX, CR, PT, XA | 168 | ||
| CPTAC-SAR | Sarcomas | Soft Tissue | CT,MR | 22 | 88 |
Corpus Endometrial Carcinoma | Uterus | CT, MR, PT, CR, DX | 250 |
*links go to TCIA NBIA radiological search portal
** links go to TCIA CPTAC Pathology Portal
Quick introduction to the TCIA CPTAC Pathology Portal:
CPTAC Phase 2 - TCGA Cancer Proteome Studies
TCIA did not formally participate in CPTAC phase 2, but a small subset of the radiology imaging studies for this cohort are available due to overlap with NIH's Cancer Genome Atlas activity. Specifically there are 28 ovarian (TCGA-OV) and 14 breast (TCGA-BRCA) cases in TCIA which have corresponding CPTAC phase 2 proteomic analysis data. The Proteomic Analysis Data is available at: https://cptac-data-portal.georgetown.edu/cptacPublic/.
Images and Clinical Data Downloads
These subsets of radiology images can be accessed using the following links:
The clinical data for these subjects can be found in these spreadsheets:
References
An early CPTAC publication which reports on a more comprehensive collection of cases from those TCGA tumor data collections (BRCA and OV) can be found at: “Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes”. Xu Z, et al., J Proteome Res. 2015 Jan 2;14(1):422-33. doi: 10.1021/pr500840w.
An excellent review of proteomic biomarkers is the publication: "Proteomics in cancer biomarkers discovery: challenges and applications." Sallam RM1. Dis Markers. 2015;2015:321370. doi: 10.1155/2015/321370.
Also: Identification of protein biomarkers in human serum using iTRAQ and shotgun mass spectrometry Methods Mol Biol. 2013;1061:291-307. doi: 10.1007/978-1-62703-589-7_18. Koutroukides TA1